Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285375 | 0.95 | GCGR (0.40) | GCGRTLR8TLR7 | |
| SCHEMBL285872 | 0.89 | CYP1A2 (0.35) | GCGRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15255830 | 0.85 | TLR8 (0.34) | TP53GAAMLYCDTLR8TLR7 | |
| SCHEMBL8995000 | 0.82 | TLR8 (0.38) | GCGRTP53GAATLR8TLR7 | |
| SCHEMBL285798 | 0.81 | LMNA (0.33) | TP53GAAMLYCDTLR8TLR7 | |
| SCHEMBL285480 | 0.81 | TLR8 (0.36) | TP53GAAMLYCDTLR8TLR7 | |
| SCHEMBL13059078 | 0.80 | NPSR1 (0.37) | GCGRNPC1RAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL2616802 | 0.74 | LMNA (0.43) | TP53GAATLR8TLR7SMN1; SMN2 | |
| SCHEMBL6050412 | 0.73 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL27865424 | 0.73 | TP53 (0.30) | TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2427458-B1 | Isoxazole-pyridazine derivatives | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| EP-2424863-B1 | ISOXAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2398782-B1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| EP-2427457-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8410104-B2 | Pyridazines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2401271-B1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER AS GABA A ALPHA5 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-8389550-B2 | Isoxazoles / O-pyridines with ethyl and ethenyl linker | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8357703-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8227461-B2 | Isoxazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2010127975-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127974-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127978-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010125042-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280019-A1 | ISOXAZOLES | JAKOB-ROETNE ROLAND | 2010-11-04 | — | — | US | disclosed |
| US-20100280020-A1 | ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-11-04 | — | — | US | disclosed |
| WO-2010097368-A1 | ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010094669-A1 | ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | ROCHE PALO ALTO LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | ROCHE PALO ALTO LLC | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210651-A1 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES | GABRA5, GABRA1, GABRA4 | GCGR 273/4885TP53 3475/4885GAA 1267/4885 |
| US-20100216845-A1 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER | GABRA5, GABRA1, GABRA4 | GCGR 326/4885TP53 4685/4885GAA 2853/4885 |
| US-20100280020-A1 | ISOXAZOLES | GABRA5, GABRA1, GABRA3 | GCGR 104/4885TP53 4803/4885GAA 1902/4885 |
| US-20100280019-A1 | ISOXAZOLES | GABRA5, GABRA1, GABRA3 | GCGR 104/4885TP53 4803/4885GAA 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.